Program
AJ201
A development code. Also written as “ALZ002 DS”.
Its studies are mostly in Bulbo-Spinal Atrophy, X-Linked, led by AnnJi Pharmaceutical.
Furthest: phase 2, since Aug 23, 20223 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AnnJi Pharmaceutical | 31 open or running | phase 2since Aug 23, 2022 | May 10, 2020 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 10, 2020First study: phase 1 study in HealthyFirst studyNCT04392830 · 72 enrolled · Australia
- Aug 23, 2022Phase 2 study in Bulbo-Spinal Atrophy, X-LinkedNCT05517603 · 25 enrolled · United States
- Apr 19, 2026Phase 1 study in Healthy Male AdultsNCT07549919 · 26 planned · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07549919Healthy Male Adults · United States | 1 | Recruiting | Apr 22, 2026 | 26 |
| NCT05517603Bulbo-Spinal Atrophy, X-Linked · United States | 2 | Completed | Apr 8, 2024 | 25 |
| NCT04392830Healthy · Australia | 1 | Completed | Apr 28, 2021 | 72 |
How it is read
Names in the registry
- “AJ201”, 2 entries
- “ALZ002 DS”, 1 entry
Codes read as this program: AJ201, ALZ002.
Conditions, from the studies’ own filings
- Bulbo-Spinal Atrophy, X-Linked, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.